Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, talks on chimeric antigen receptor T-cell (CAR-T) therapies in multiple myeloma, commenting on the recent approval of ciltacabtagene autoleucel (cilta-cel). The first CAR-T product was approved in pediatric and young adult patients with acute lymphoblastic leukemia (ALL), and its use was later expanded to treat a larger number of indications. The first CAR-T product in multiple myeloma, idecabtagene vicleucel, was approved in 2021 based on the results of the KarMMa trial (NCT03361748). More recently, the highly promising results from the CARTITUDE-1 trial (NCT03548207) led to the approval of cilta-cel by the FDA. According to Prof. Mohty, the addition of cilta-cel to the treatment armamentarium in multiple myeloma will undoubtedly improve the outcomes of patients with R/R disease, and he believes that CAR-Ts will start being used in earlier lines of treatment. Several trials are already comparing CAR-T products versus existing standards of care (SOC) in myeloma. This interview took place at the 48th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) 2022, which was held virtually.